Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | PLAUR | Q03405 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077282 | 0.89 | SIGMAR1 (0.38) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL10413132 | 0.86 | SIGMAR1 (0.43) | SIGMAR1OPRD1PLAUPLAURSLC6A4 | |
| SCHEMBL1900357 | 0.85 | SIGMAR1 (0.58) | SIGMAR1OPRD1CHRM5CHRM3 | |
| SCHEMBL6032886 | 0.83 | SIGMAR1 (0.41) | SIGMAR1OPRD1PLAUPLAURSLC6A4 | |
| SCHEMBL2764645 | 0.82 | SIGMAR1 (0.38) | SIGMAR1OPRD1PLAUPLAURSLC6A4 | |
| SCHEMBL1905214 | 0.81 | SIGMAR1 (0.47) | SIGMAR1SLC6A4 | |
| SCHEMBL9162742 | 0.80 | PLAU (0.36) | SIGMAR1OPRD1PLAUPLAURSLC6A4 | |
| SCHEMBL4557394 | 0.77 | MEN1 (0.39) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 | |
| SCHEMBL8488533 | 0.77 | PLAU (0.36) | SIGMAR1OPRD1PLAUPLAURSLC6A4 | |
| SCHEMBL28716337 | 0.75 | LMNA (0.45) | SIGMAR1OPRD1SLC6A4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801522-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | SIGMAR1 218/4885OPRD1 302/4885PLAU 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.